Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

BACKGROUND: The use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity. METHODS: We stained human natural killer cells using fusion proteins composed of the extracellular po...

Descripción completa

Detalles Bibliográficos
Autores principales: Reches, Adi, Ophir, Yael, Stein, Natan, Kol, Inbal, Isaacson, Batya, Charpak Amikam, Yoav, Elnekave, Afek, Tsukerman, Pinchas, Kucan Brlic, Paola, Lenac, Tihana, Seliger, Barbara, Jonjic, Stipan, Mandelboim, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279670/
https://www.ncbi.nlm.nih.gov/pubmed/32503945
http://dx.doi.org/10.1136/jitc-2019-000266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279670/
https://www.ncbi.nlm.nih.gov/pubmed/32503945
http://dx.doi.org/10.1136/jitc-2019-000266

Ejemplares similares